Get your Pfizer COVID-19 vaccine. Walk-ins welcome! Mon., Wed., Fri.: 8 a.m. - 5 p.m. and Tues., Thurs.: 8 a.m. - 7 p.m. >

A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia

Investigator: Dale Hamilton, MD

Study Coordinator: Melissa Whipple

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT02304367

Phone: 713.441.3247

Protocol Number: Pro00012876

Description

The primary objectives of this study are to evaluate the effect of KRN23 treatment on: Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia Improvement in TIO/ENS-associated osteomalacia as determined by osteoid thickness (O.Th), osteoid surface/bone surface (OS/BS), osteoid volume/bone volume (OV/BV) and mineralization lag time (MLt).
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials